1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > 2015 Deep Research Report on Global Biologics and Biosimilars Industry

Summary

2015 Deep Research Report on Global Biologics and Biosimilars Industry is a professional and depth research report on Global Biologics and Biosimilars industry.

For overview analysis, the report introduces Biologics and Biosimilars basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.

For international and China market analysis, the report analyzes Biologics and Biosimilars markets in China and other countries or regions (such as Asia, Europe, North America etc) by presenting research on global products of different types and applications, developments and trends of market, technology, and competitive landscape, and leading suppliers and countries’ 2010-2015 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as production value, customers, application, market position, and company contact information, etc. 2016-2021 forecast on production value for these markets are also included.

For technical data and manufacturing plants analysis, the report analyzes Biologics and Biosimilars leading suppliers on commercial production value, manufacturing plants distribution, R&D Status, technology sources, and raw materials sources.

This report also presents product specification, manufacturing process, and product value etc. Production is separated by regions, technology and applications. Analysis also covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals.

In the end, the report includes Biologics and Biosimilars new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. In conclusion, it is a deep research report on Global Biologics and Biosimilars industry. Here, we express our thanks for the support and assistance from Biologics and Biosimilars industry chain related technical experts and marketing engineers during Research Team’s survey and interviews.

Table Of Contents

2015 Deep Research Report on Global Biologics and Biosimilars Industry
Table of Contents

Chapter One Biologics and Biosimilars Industry Overview 1
1.1 Biologics and Biosimilars Definition 1
1.2 Biologics and Biosimilars Classification and Application 5
1.3 Biologics and Biosimilars Industry Chain Structure 7
1.4 Biologics and Biosimilars Industry Overview 7
1.5 Biologics and Biosimilars Industry Policy Analysis 8
1.6 Biologics and Biosimilars Industry News Analysis 9

Chapter Two Biologics and Biosimilars International and China Market Analysis 11
2.1 Biologics and Biosimilars Industry International Market Analysis 11
2.1.1 Biologics and Biosimilars International Market Development History 11
2.1.2 Biologics and Biosimilars Product and Technology Developments 12
2.1.3 Biologics and Biosimilars Competitive Landscape Analysis 14
2.1.4 Biologics and Biosimilars International Key Countries Development Status 15
2.1.5 Biologics and Biosimilars International Market Development Trend 16
2.2 Biologics and Biosimilars Industry China Market Analysis 17
2.2.1 Biologics and Biosimilars China Market Development History 17
2.2.2 Biologics and Biosimilars Product and Technology Developments 18
2.2.3 Biologics and Biosimilars Competitive Landscape Analysis 20

Chapter Three Biologics and Biosimilars Technical Data Analysis 21
3.1 2010-2015E Global Key Manufacturers Biologics Revenue Structure Analysis 21
3.2 2010-2015E Global Key Manufacturers Biosimilars Revenue Structure Analysis 21

Chapter Four Biologics and Biosimilars Patent Analysis 23
4.1 2013 Global Top Ten Biosimilars Products Sales Analysis 23
4.2 Biological Medicines with Patents about to expire or expired 24

Chapter Five Biologics and Biosimilars Manufacturing Process and Cost Structure 24
5.1 Biologics and Biosimilars Product Specifications 24
5.2 Biologics and Biosimilars Manufacturing Process Analysis 26
5.3 Biologics and Biosimilars Marketing Process Analysis 28
5.4 Biologics and Biosimilars Approval Process Analysis 28
5.5 Biologics and Biosimilars Cost Structure Analysis 29
5.6 Biologics and Biosimilars Price Analysis 30

Chapter Six 2010-2015E Biologics and Biosimilars Productions Supply Sales Demand Market Status 30
6.1 2010-2015E Biologics Industry Overview 30
6.2 2010-2015E Biosimilars Industry Overview 40

Chapter Seven Biologics and Biosimilar Major Manufacturers Analysis 46
Biologics 46
7.1 Pfizer 46
7.1.1 Company Profile 47
7.1.2 Sales (Million $) Sales growth rate 50
7.1.3 Contact Information 51
7.2 Roche 51
7.2.1 Company Profile 51
7.2.2 Sales (Million $) Sales growth rate 53
7.2.3 Contact Information 54
7.3 Amgen 54
7.3.1 Company Profile 54
7.3.2 Sales (Million $) Sales growth rate 56
7.3.3 Contact Information 57
7.4 AbbVie 58
7.4.1 Company Profile 58
7.4.2 Sales (Million $) Sales growth rate 59
7.4.3 Contact Information 60
7.5 Sanofi 60
7.5.1 Company Profile 61
7.5.2 Sales (Million $) Sales growth rate 64
7.5.3 Contact Information 65
7.6 Johnson and Johnson 65
7.6.1 Company Profile 65
7.6.2 Sales (Million $) Sales growth rate 67
7.6.3 Contact Information 68
7.7 Novo Nordisk 68
7.7.1 Company Profile 69
7.7.2 Sales (Million $) Sales growth rate 70
7.7.3 Contact Information 71
7.8 Novartis 71
7.8.1 Company Profile 72
7.8.2 Sales (Million $) Sales growth rate 73
7.8.3 Contact Information 74
7.9 Merck 75
7.9.1 Company Profile 75
7.9.2 Sales (Million $) Sales growth rate 77
7.9.3 Contact Information 78
7.10 Lilly 79
7.10.1 Company Profile 79
7.10.2 Sales (Million $) Sales growth rate 81
7.10.3 Contact Information 82
7.11 3sbio 83
7.11.1 Company Profile 83
7.11.2 Sales (Million $) Sales growth rate 84
7.11.3 Contact Information 85
7.12 Changchun High and New Technology Industry (Group) Inc. 86
7.12.1 Company Profile 86
7.12.2 Sales (Million $) Sales growth rate 86
7.12.3 Contact Information 87
7.13 CP Guojian Pharmacy 88
7.13.1 Company Profile 88
7.13.2 Sales (Million $) Sales growth rate 88
7.13.3 Contact Information 89
7.14 Biotech Pharma 89
7.1.1 Company Profile 89
7.14.2 Sales (Million $) Sales growth rate 90
7.14.3 Contact Information 91
7.15 Gelgen Biopharma 91
7.15.1 Company Profile 92
7.15.2 Sales (Million $) Sales growth rate 93
7.15.3 Contact Information 94
Biosimilar 95
7.1 SANDOZ (NOVARTIS) 95
7.1.1 Company Profile 95
7.1.2 Sales (Million $) Sales growth rate 96
7.1.3 Contact Information 97
7.2 Teva Pharmaceutical Industries 98
7.2.1 Company Profile 98
7.2.2 Sales (Million $) Sales growth rate 99
7.2.3 Contact Information 100
7.3 Hospira ?Pfizer? 100
7.3.1 Company Profile 100
7.3.2 Sales (Million $) Sales growth rate 101
7.1.3 Contact Information 102
7.4 MYLAN INC. 102
7.4.1 Company Profile 102
7.4.2 Sales (Million $) Sales growth rate 103
7.4.3 Contact Information 104
7.5 3sbio 105
7.5.1 Company Profile 105
7.5.2 Sales (Million $) Sales growth rate 106
7.5.3 Contact Information 107
7.6 Changchun High and New Technology Industry (Group) Inc. 108
7.6.1 Company Profile 108
7.6.2 Sales (Million $) Sales growth rate 108
7.6.3 Contact Information 109
7.7 CP Guojian Pharmacy 110
7.7.1 Company Profile 110
7.7.2 Sales (Million $) Sales growth rate 110
7.7.3 Contact Information 111
7.8 Biotech Pharma 111
7.8.1 Company Profile 111
7.8.2 Sales (Million $) Sales growth rate 112
7.8.3 Contact Information 113
7.9 Gelgen Biopharma 113
7.9.1 Company Profile 114
7.9.2 Sales (Million $) Sales growth rate 115
7.9.3 Contact Information 116

Chapter Eight Biologics and Biosimilars Industry Chain Structure Analysis 117
8.1 Biologics Segment Market Analyses 117
8.2 Biologics and Biosimilars Industry Development in Emerging Markets 118
8.3 Key Applications and Consumption Analysis 119
8.4 Key Regions and Consumption Analysis 121

Chapter Nine Biologics and Biosimilars Marketing Channels Analysis 123
9.1 Biologics and Biosimilars Marketing Channels Status 123
9.2 Biologics and Biosimilars Marketing Channels Characteristic 124
9.3 Biologics and Biosimilars Marketing Channels Development Trend 125

Chapter Ten 2015E-2021 Biologics and Biosimilars Productions Supply Sales Demand Market Status and Forecast 128
10.1 2015E-2021 Biologics Market Status and Forecast 128
10.2 2015E-2021 Biosimilars Market Status and Forecast 129

Chapter Eleven Paclitaxel Industry Development Proposals 131
11.1 Macroeconomic Development Countermeasures 131
11.1.1 Specific control measures 133
11.1.2 Key success factors between Mature Countries and Emerging Countries 135
11.1.3 Macroeconomic policy 136
11.2 New Firms Enter Market Strategy 137
11.3 New Project Investment Proposals 140
11.4 Competitive Environment Strategy Proposals 141

Chapter Twelve Biologics and Biosimilars New Project Investment Feasibility Analysis 142
12.1 Biologics and Biosimilars Project SWOT Analysis 142
12.2 Biologics and Biosimilars Project PEST Analysis 142
12.2.1 Political Factors 142
12.2.2 Economic Factors 143
12.2.3 Sociocultural Factors 153
12.2.4 Technological Factors 154

Chapter Thirteen Global Biologics and Biosimilars Industry Research Conclusions 155

Tables and Figures

Figure Biologics and Biosimilars Product Picture 1
Figure Biologics Product Picture 2
Figure Biosimilars Product Picture 2
Table Difference between biologics and biosimilar: 3
Table Biosimilars Classification and Application List 5
Figure Biologics and Biosimilars Industry Chain Structure 7
Figure 2014 Global FOB Policy and Regulations 9
Table Global Major Generic Companies Active in FOB Development List 12
Table 2012-2016 Patent Expirations Brand in US, Japan, UK, France and Germany 12
Figure 2014 Global Major Manufacturers Biologics Sales Market Share 14
Figure 2014 Global Major Manufacturers Biosimilars Sales Market Share 15
Figure 2014 Global Major Countries Biologics Sales Market Share 15
Figure 2014 Global Major Countries Biosimilars Sales Market Share 16
Figure 2015-2020 Global Biologics Sales and Growth Rate 16
Figure 2015-2020 Global Biosimilars Sales and Growth Rate 17
Figure 2010-2014 China Number of New Drugs Approved 18
Figure Innovation Fund Invested on Biologics Industry Trend 19
Figure 2014 China Major Manufacturers Biologics Sales Market Share 20
Figure 2014 China Major Manufacturers Biosimilars Sales Market Share 20
Table 2010-2015E Global Key Manufacturers Biologics Proportion of Revenues List 21
Table 2010-2015E Global Key Manufacturers Biosimilars Proportion of Revenues List 21
Table 2013 Global Top Ten Biosimilars Products Sales (billion USD) List 23
Table Biological Medicines with Patents about to expire or expire List 24
Table Difference of Specifications between Original Chemical Drugs and Biologics List 25
Table Difference of Specifications among Original Biologics, Biosimilars and Chemical Generics List 26
Figure Biologics and Biosimilars Marketing Process 28
Figure 2014 Biologics and Biosimilars Cost Structure List 29
Table 2010-2015E Global Major Manufacturers Biologics Sales and Total Sales List 30
Table 2010-2015E Global Major Manufacturers Biologics Sales Market Share List 31
Figure 2010 Global Major Manufacturers Biologics Sales Market Share 32
Figure 2011 Global Major Manufacturers Biologics Sales Market Share 33
Figure 2012 Global Major Manufacturers Biologics Sales Market Share 34
Figure 2013 Global Major Manufacturers Biologics Sales Market Share 35
Figure 2014 Global Major Manufacturers Biologics Sales Market Share 36
Table 2010-2015E China Major Manufacturers Biologics Sales and Total Sales List 36
Table 2010-2015E China Major Manufacturers Biologics Sales and Total Sales Market Share List 37
Figure 2010 China Major Manufacturers Biologics Sales Market Share 37
Figure 2011 China Major Manufacturers Biologics Sales Market Share 38
Figure 2012 China Major Manufacturers Biologics Sales Market Share 38
Figure 2013 China Major Manufacturers Biologics Sales Market Share 39
Figure 2014 China Major Manufacturers Biologics Sales Market Share 39
Table 2010-2015E Global Major Manufacturers Biosimilars Sales and Total Sales List 40
Table 2010-2015E Global Major Manufacturers Biosimilars Sales Market Share List 40
Figure 2010 Global Major Manufacturers Biosimilars Sales Market Share 41
Figure 2011 Global Major Manufacturers Biosimilars Sales Market Share 41
Figure 2012 Global Major Manufacturers Biosimilars Sales Market Share 42
Figure 2013 Global Major Manufacturers Biosimilars Sales Market Share 42
Figure 2014 Global Major Manufacturers Biosimilars Sales Market Share 43
Table 2010-2015E China Major Manufacturers Biosimilars Sales and Total Sales List 43
Table 2010-2015E China Major Manufacturers Biosimilars Sales and Total Sales Market Share List 43
Figure 2010 China Major Manufacturers Biosimilars Sales Market Share 44
Figure 2011 China Major Manufacturers Biosimilars Sales Market Share 44
Figure 2012 China Major Manufacturers Biosimilars Sales Market Share 45
Figure 2013 China Major Manufacturers Biosimilars Sales Market Share 45
Figure 2014 China Major Manufacturers Biosimilars Sales Market Share 46
Table 2010-2015E Pfizer Biologics Sales (Million $) and Growth Rate 50
Figure 2010-2015E Pfizer Biologics Sales (Million $) and Growth Rate 50
Figure 2010-2015E Pfizer Biologics Sales (Million $) and Global Market Share 50
Table 2010-2015E Roche Biologics Sales (Million $) and Growth Rate 53
Figure 2010-2015E Roche Biologics Sales (Million $) and Growth Rate 53
Figure 2010-2015E Roche Biologics Sales (Million $) and Global Market Share 54
Table 2010-2015E Amgen Biologics Sales (Million $) and Growth Rate 56
Figure 2010-2015E Amgen Biologics Sales (Million $) and Growth Rate 57
Figure 2010-2015E Amgen Biologics Sales (Million $) and Global Market Share 57
Table 2010-2015E AbbVie Biologics Sales (Million $) and Growth Rate 59
Figure 2010-2015E AbbVie Biologics Sales (Million $) and Growth Rate 59
Figure 2010-2015E AbbVie Biologics Sales (Million $) and Global Market Share 60
Table 2010-2015E Sanofi Biologics Sales (Million $) and Growth Rate 64
Figure 2010-2015E Sanofi Biologics Sales (Million $) and Growth Rate 64
Figure 2010-2015E Sanofi Biologics Sales (Million $) and Global Market Share 64
Table 2010-2015E Johnson and Johnson Biologics Sales (Million $) and Growth Rate 67
Figure 2010-2015E Johnson and Johnson Biologics Sales (Million $) and Growth Rate 67
Figure 2010-2015E Johnson and Johnson Biologics Sales (Million $) and Global Market Share 68
Table 2010-2015E Novo Nordisk Biologics Sales (Million $) and Growth Rate 70
Figure 2010-2015E Novo Nordisk Biologics Sales (Million $) and Growth Rate 70
Figure 2010-2015E Novo Nordisk Biologics Sales (Million $) and Global Market Share 71
Table 2010-2015E Novartis Biologics Sales (Million $) and Growth Rate 73
Figure 2010-2015E Novartis Biologics Sales (Million $) and Growth Rate 74
Figure 2010-2015E Novartis Biologics Sales (Million $) and Global Market Share 74
Table 2010-2015E Merck Biologics Sales (Million $) and Growth Rate 77
Figure 2010-2015E Merck Biologics Sales (Million $) and Growth Rate 78
Figure 2010-2015E Merck Biologics Sales (Million $) and Global Market Share 78
Table 2010-2015E Lilly Biologics Sales (Million $) and Growth Rate 81
Figure 2010-2015E Lilly Biologics Sales (Million $) and Growth Rate 82
Figure 2010-2015E Lilly Biologics Sales (Million $) and Global Market Share 82
Table 2010-2015E 3sbio Biologics Sales (Million $) and Growth Rate 84
Figure 2010-2015E 3sbio Biologics Sales (Million $) and Growth Rate 85
Figure 2010-2015E 3sbio Biologics Sales (Million $) and Global Market Share 85
Table 2010-2015 Changchun High and New Technology Industry (Group) Inc. Biologics Sales (Million $) and Growth Rate 86
Figure 2010-2015 Changchun High and New Technology Industry (Group) Inc. Biologics Sales (Million $) and Growth Rate 87
Figure 2010-2015 Changchun High and New Technology Industry (Group) Inc. Biologics Sales (Million $) and Global Market Share 87
Table 2010-2015 CP Guojian Pharmacy Biologics Sales (Million $) and Growth Rate 88
Figure 2010-2015 CP Guojian Pharmacy Biologics Sales (Million $) and Growth Rate 88
Figure 2010-2015 CP Guojian Pharmacy Biologics Sales (Million $) and Global Market Share 89
Table 2010-2015 Biotech Pharma Biologics Sales (Million $) and Growth Rate 90
Figure 2010-2015 Biotech Pharma Biologics Sales (Million $) and Growth Rate 90
Figure 2010-2015 Biotech Pharma Biologics Sales (Million $) and Global Market Share 91
Table 2010-2015E Gelgen Biopharma Biologics Sales (Million $) and Growth Rate 93
Figure 2010-2015E Gelgen Biopharma Biologics Sales (Million $) and Growth Rate 94
Figure 2010-2015E Gelgen Biopharma Biologics Sales (Million $) and Global Market Share 94
Table 2010-2015 SANDOZ (NOVARTIS) Biosimilar Sales (Million $) and Growth Rate 96
Figure 2010-2015 SANDOZ (NOVARTIS) Biosimilar Sales (Million $) and Growth Rate 97
Figure 2010-2015 SANDOZ (NOVARTIS) Biosimilar Sales (Million $) and Global Market Share 97
Table 2010-2015 Teva Pharmaceutical Industries Biosimilar Sales (Million $) and Growth Rate 99
Figure 2010-2015 Teva Pharmaceutical Industries Biosimilar Sales (Million $) and Growth Rate 99
Figure 2010-2015 Teva Pharmaceutical Industries Biosimilar Sales (Million $) and Global Market Share 100
Table 2010-2015 Pfizer Biosimilar Sales (Million $) and Growth Rate 101
Figure 2010-2015 Pfizer Biosimilar Sales (Million $) and Growth Rate 101
Figure 2010-2015 Pfizer Biosimilar Sales (Million $) and Global Market Share 102
Table 2010-2015 MYLAN INC. Biosimilar Sales (Million $) and Growth Rate 103
Figure 2010-2015 MYLAN INC. Biosimilar Sales (Million $) and Growth Rate 104
Figure 2010-2015 MYLAN INC. Biosimilar Sales (Million $) and Global Market Share 104
Table 2010-2015E 3sbio Biosimilar Sales (Million $) and Growth Rate 106
Figure 2010-2015E 3sbio Biosimilar Sales (Million $) and Growth Rate 107
Figure 2010-2015E 3sbio Biosimilar Sales (Million $) and Global Market Share 107
Table 2010-2015 Changchun High and New Technology Industry (Group) Inc. Biosimilar Sales (Million $) and Growth Rate 108
Figure 2010-2015 Changchun High and New Technology Industry (Group) Inc. Biosimilar Sales (Million $) and Growth Rate 109
Figure 2010-2015 Changchun High and New Technology Industry (Group) Inc. Biosimilar Sales (Million $) and Global Market Share 109
Table 2010-2015 CP Guojian Pharmacy Biosimilar Sales (Million $) and Growth Rate 110
Figure 2010-2015 CP Guojian Pharmacy Biosimilar Sales (Million $) and Growth Rate 110
Figure 2010-2015 CP Guojian Pharmacy Biosimilar Sales (Million $) and Global Market Share 111
Table 2010-2015 Biotech Pharma Biosimilar Sales (Million $) and Growth Rate 112
Figure 2010-2015 Biotech Pharma Biosimilar Sales (Million $) and Growth Rate 112
Figure 2010-2015 Biotech Pharma Biosimilar Sales (Million $) and Global Market Share 113
Table 2010-2015E Gelgen Biopharma Biosimilar Sales (Million $) and Growth Rate 115
Figure 2010-2015E Gelgen Biopharma Biosimilar Sales (Million $) and Growth Rate 116
Figure 2010-2015E Gelgen Biopharma Biosimilar Sales (Million $) and Global Market Share 116
Figure Biologics Global Market Share and Share of Biologics by Sales 117
Figure Spending on Biologics in Emerging Markets 118
Figure Recombinant Protein Production in Emerging Markets 119
Table 2014 China Infective Population of Several Diseases 119
Figure 2014 Global Biologics in Research Statistics by Indications 120
Figure the biologics with more than 1Bn USD by country 120
Figure Data exclusivity period 121
Figure 2014 Global Biologics Consumption Market Share by Regions 121
Figure 2014 Global Biosimilars Consumption Market Share by Regions 121
Table 2003, 2008 and 2013 Global Pharmaceutical Market Scale Ranking 121
Figure Beset sales biologics patent 122
Figure Biologics and Biosimilars Domestic Marketing Channels Status 123
Figure Imported Biologics and Biosimilars Marketing Channels Status 124
Figure 4 P' S Marketing model 126
Figure 7 P' S Marketing model 127
Table 2015E-2021 Global Biologics Sales (Million $) and Growth Rate 128
Figure 2015E-2021 Global Biologics Sales and Growth Rate 128
Table 2015E-2021 China Biologics Sales (Million $) and Growth Rate 128
Figure 2015E-2021 China Biologics Sales and Growth Rate 129
Table 2015E-2021 Global Biosimilars Sales (Million $) and Growth Rate 129
Figure 2015E-2021 Global Biosimilars Sales and Growth Rate 130
Table 2015E-2021 China Biosimilars Sales (Million $) and Growth Rate 130
Figure 2015E-2021 China Biosimilars Sales and Growth Rate 130
Figure Health and Care Industry market trend in China 132
Figure characteristics that influence the background of Health and Care Industry market in China 133
Table factors vary according to the level of economic development 135
Table New Firms Enter Market Strategy 137
Figure administration on start up 139
Figure Share of GDP according to the size of the companies 140
Table New Project Investment Proposals 140
Figure European private equity funds raised in 2010 141
Table Competitive Environment Strategy Proposals 141
Table Biologics and Biosimilars New Project SWOT Analysis for Chinese Company 142
Figure 2007-2013 China GDP (100 million RMB) and Growth Rate 143
Figure 2007-2013 China CPI Change Trend 144
Figure 2007-2013 China Urban and Rural Incomes (RMB) 145
Figure 2007-2013 China Total Retail Sales of Consumer Goods (100 million RMB) and Growth Rate 146
Figure 2007-2013 China Investment in Fixed Assets (100 million RMB) and Growth Rate 147
Figure 2007-2013 China the Total Value of Imports and Exports of Goods (100 million USD) and Growth Rate 148
Table 2014 China Macroeconomic Forecast Key Indicators (%) 149
Figure 2007-2013 EU27 GDP Growth Rate 149
Figure 2007-2013 EU27 HICP Index (The month of year-on-year) 150
Figure 2007-2013 United States GDP (100 million USD) 150
Figure 2007-2013 United States CPI 151
Figure 2007-2013 Japan GDP (Billion Yen) 151
Figure 2007-2013 Japan CPI (The month of year-on-year) 152
Figure 1993-2013 Global Incidences of Malignant Tumors 154
Figure the amount of biosimilar in research 155

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.